黑料网

Stem cell transplantation; Leukemia treatment; Surgical procedures; Autologous transplantation; Allogeneic transplantation

Introduction

Stem cell transplantation (SCT) represents a critical treatment option for leukemia patients, offering the potential for long-term disease remission and cure. This article explores the surgical procedures involved in stem cell transplantation for leukemia, along with the recovery process and considerations for patient care [1].

Stem cell transplantation

Stem cell transplantation is a procedure used to replace damaged or diseased bone marrow with healthy stem cells, which can restore normal blood cell production in patients with leukemia. It is primarily indicated for patients with high-risk or relapsed leukemia, where conventional therapies have not been successful in achieving remission [2].

Types of stem cell transplantation

There are two main types of stem cell transplantation used in leukemia treatment:

Autologous stem cell transplantation: In this procedure, the patient's own stem cells are collected and stored prior to receiving high-dose chemotherapy or radiation therapy. After treatment, the stored stem cells are infused back into the patient to help regenerate healthy bone marrow.

Allogeneic stem cell transplantation: This involves using stem cells from a matched donor, typically a sibling or unrelated donor, whose tissue type closely matches that of the patient. Allogeneic transplantation offers the potential for graft-versus-leukemia effect, where the donor immune cells recognize and eliminate remaining leukemia cells [3].

Surgical procedures in stem cell transplantation

Stem cell harvesting

For autologous transplantation, stem cells are collected from the patient's blood using a process called apheresis. Blood is withdrawn from the patient, passed through a machine that separates out the stem cells, and the remaining blood components are returned to the patient.

Allogeneic transplantation requires the donor to undergo a similar stem cell harvesting process.

Conditioning regimen

Before receiving the donor stem cells or their own previously collected stem cells, patients undergo a conditioning regimen. This involves high-dose chemotherapy and sometimes radiation therapy to destroy remaining leukemia cells and suppress the patient's immune system to prevent rejection of the donor stem cells [4].

Stem cell infusion

After completing the conditioning regimen, the collected stem cells are infused into the patient through a central venous catheter, similar to a blood transfusion. The stem cells travel to the bone marrow, where they begin producing new blood cells.

Recovery and post-transplant care

The recovery phase following stem cell transplantation is critical and involves close monitoring for complications such as infections, graftversus- host disease (GVHD), and organ toxicity from the conditioning regimen. Patients may require supportive care, including antibiotics, antifungals, and blood transfusions, to manage these complications [5].

Engraftment: Monitoring for engraftment, when the donor stem cells begin producing new blood cells, is essential. Blood counts are closely monitored to assess the success of transplantation.

Immunosuppression: Patients undergoing allogeneic transplantation require immunosuppressive medications to prevent GVHD, where donor immune cells attack the patient's tissues.

Long-term follow-up: Long-term follow-up care focuses on monitoring for leukemia recurrence, managing late effects of treatment, and supporting patients in maintaining their overall health and wellbeing.

Challenges and advances

Stem cell transplantation is associated with risks and challenges, including complications from conditioning regimens, graft rejection or failure, and GVHD. Advances in transplantation techniques, supportive care strategies, and donor selection criteria continue to improve outcomes and reduce these risks, expanding the potential for successful treatment in leukemia patients [6].

Discussion

Stem cell transplantation (SCT) stands as a pivotal treatment modality for leukemia, offering a potential cure for patients with high-risk or relapsed disease. This discussion delves into the surgical procedures involved in SCT for leukemia, the recovery process, and the significant considerations that shape patient outcomes.

Autologous Transplantation: For autologous SCT, patients undergo stem cell harvesting, where their own stem cells are collected from peripheral blood through apheresis. This process involves separating stem cells from other blood components, followed by cryopreservation for later infusion after chemotherapy [7].

Allogeneic Transplantation: In contrast, allogeneic SCT requires a donor whose tissue type closely matches that of the recipient. Donor stem cells are harvested through apheresis or, less commonly, from bone marrow extraction.

Before stem cell infusion, patients receive a conditioning regimen comprising high-dose chemotherapy and sometimes total body irradiation. This intensive treatment aims to eradicate residual leukemia cells, suppress the patient's immune system, and create space within the bone marrow for engraftment of donor stem cells.

The collected stem cells are infused into the patient through a central venous catheter, similar to a blood transfusion. Once infused, the stem cells travel to the bone marrow, where they begin to regenerate and produce healthy blood cells [8].

Monitoring for engraftment is crucial, as it signifies successful integration of donor stem cells into the patient's bone marrow. Blood counts are closely monitored to assess the production of white blood cells, red blood cells, and platelets, which typically begins within two to four weeks after transplantation.

Patients are at risk for complications such as infections, graftversus- host disease (GVHD), and organ toxicity from the conditioning regimen. Prophylactic antibiotics, antivirals, and antifungals are often administered to prevent infections, while immunosuppressive medications are used to manage GVHD in allogeneic SCT recipients [9].

Long-term follow-up care focuses on monitoring for leukemia recurrence, managing late effects of treatment, and supporting patients in maintaining their overall health and well-being. Psychological support is also essential, as patients may experience emotional challenges during the recovery and survivorship phases.

Ensuring compatibility between donor and recipient is crucial to minimize the risk of graft rejection or failure. Allogeneic SCT carries the risk of GVHD, where donor immune cells attack the recipient's tissues, requiring ongoing management with immunosuppressive therapy.

Immunosuppression post-transplantation increases susceptibility to infections, necessitating vigilant monitoring and prophylactic measures. Advancements in SCT techniques, including improved donor selection, supportive care strategies, and reduced-intensity conditioning regimens, have enhanced outcomes and expanded the applicability of transplantation to older and medically fragile patients [10].

Conclusion

In conclusion, stem cell transplantation plays a crucial role in the treatment of leukemia, offering a potential cure for patients with high-risk or relapsed disease. Understanding the surgical procedures involved, the recovery process, and the complexities of post-transplant care is essential for healthcare providers and patients alike. Ongoing research and clinical advancements aim to further refine transplantation techniques, enhance patient outcomes, and improve quality of life for individuals undergoing this life-saving procedure.

References

1. Jeong J, Kim SY, Han SH (1998) . Electroencephalogr Clin Neurophysiol 106: 220-228.

, ,

2. Dunkin JJ, Leuchter AF, Newton TF, Cook IA (1994) ? Biol Psychiatry 35:870-879.

 , ,

3.  Wen D, Zhou Y, Li X (2015) . Front Aging Neurosci.

, ,

4. Anguela XM, High KA (2019) . Annu Rev Med 70: 273-288.

, ,

5. Schenk D (2002) . Nat Rev Neurosci 3: 824-828.

, ,

6. Herline K, Drummond E, Wisniewski T (2018) . Expert Rev Vaccines 17: 707-721.

, ,

7. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) . Neurology 64: 1553-1562.

, ,

8. WeinstockM (1999) . CNS Drugs 12: 307-323.

          

9. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) . Methods Find Exp Clin Pharmacol 22: 609-613.

, ,

10. Holmstedt B (1972) . Cambridge University Press, Cambridge.